Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1675057rdf:typepubmed:Citationlld:pubmed
pubmed-article:1675057lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:1675057lifeskim:mentionsumls-concept:C0281361lld:lifeskim
pubmed-article:1675057lifeskim:mentionsumls-concept:C0069515lld:lifeskim
pubmed-article:1675057lifeskim:mentionsumls-concept:C1704824lld:lifeskim
pubmed-article:1675057lifeskim:mentionsumls-concept:C0017262lld:lifeskim
pubmed-article:1675057lifeskim:mentionsumls-concept:C2911684lld:lifeskim
pubmed-article:1675057lifeskim:mentionsumls-concept:C0185117lld:lifeskim
pubmed-article:1675057pubmed:issue1lld:pubmed
pubmed-article:1675057pubmed:dateCreated1991-7-17lld:pubmed
pubmed-article:1675057pubmed:abstractTextThe c-erbB-2 (neu) gene encodes a transmembrane phosphoglycoprotein (p185erbB-2) which resembles a growth factor receptor-like molecule closely related to the epidermal growth factor receptor. Overexpression of c-erbB-2 induces cell transformation in vitro. Poorer survival rates and elevated recurrence rates following treatment have been shown in patients whose breast adenocarcinomas demonstrate increased c-erbB-2 expression. Using immunoprecipitation and immunoperoxidase staining, we surveyed human cell lines for p185erbB-2. Cell lines from most tumor types (e.g. lymphomas, neuroblastomas, melanomas) demonstrated negligible p185erB-2; however, 3 of 6 pancreatic cell lines overexpressed c-erbB-2. Southern blot analysis revealed that c-erbB-2 was amplified in two of these cell lines and was both rearranged and amplified in one of them. Based on these findings, we examined tissue sections from archival specimens of primary human pancreatic adenocarcinomas. A substantial proportion of specimens had increased p185erbB-2, as judged by increased immunostaining of the tumor cells. In such pancreatic tumors p185erbB-2 may contribute to the malignant phenotype and could provide a target for immunodiagnostic or immunotherapeutic strategies.lld:pubmed
pubmed-article:1675057pubmed:languageenglld:pubmed
pubmed-article:1675057pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1675057pubmed:citationSubsetIMlld:pubmed
pubmed-article:1675057pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1675057pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1675057pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1675057pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1675057pubmed:statusMEDLINElld:pubmed
pubmed-article:1675057pubmed:issn1015-2008lld:pubmed
pubmed-article:1675057pubmed:authorpubmed-author:MaguireH...lld:pubmed
pubmed-article:1675057pubmed:authorpubmed-author:GreeneM IMIlld:pubmed
pubmed-article:1675057pubmed:authorpubmed-author:WeinerD BDBlld:pubmed
pubmed-article:1675057pubmed:authorpubmed-author:WilliamsT MTMlld:pubmed
pubmed-article:1675057pubmed:issnTypePrintlld:pubmed
pubmed-article:1675057pubmed:volume59lld:pubmed
pubmed-article:1675057pubmed:geneSymbolNGLlld:pubmed
pubmed-article:1675057pubmed:geneSymbolHER-2lld:pubmed
pubmed-article:1675057pubmed:geneSymbolneulld:pubmed
pubmed-article:1675057pubmed:geneSymbolc-erbB-2lld:pubmed
pubmed-article:1675057pubmed:geneSymbolc-erbB-2 (neu)lld:pubmed
pubmed-article:1675057pubmed:ownerNLMlld:pubmed
pubmed-article:1675057pubmed:authorsCompleteYlld:pubmed
pubmed-article:1675057pubmed:pagination46-52lld:pubmed
pubmed-article:1675057pubmed:dateRevised2009-11-19lld:pubmed
pubmed-article:1675057pubmed:meshHeadingpubmed-meshheading:1675057-...lld:pubmed
pubmed-article:1675057pubmed:meshHeadingpubmed-meshheading:1675057-...lld:pubmed
pubmed-article:1675057pubmed:meshHeadingpubmed-meshheading:1675057-...lld:pubmed
pubmed-article:1675057pubmed:meshHeadingpubmed-meshheading:1675057-...lld:pubmed
pubmed-article:1675057pubmed:meshHeadingpubmed-meshheading:1675057-...lld:pubmed
pubmed-article:1675057pubmed:meshHeadingpubmed-meshheading:1675057-...lld:pubmed
pubmed-article:1675057pubmed:meshHeadingpubmed-meshheading:1675057-...lld:pubmed
pubmed-article:1675057pubmed:meshHeadingpubmed-meshheading:1675057-...lld:pubmed
pubmed-article:1675057pubmed:meshHeadingpubmed-meshheading:1675057-...lld:pubmed
pubmed-article:1675057pubmed:meshHeadingpubmed-meshheading:1675057-...lld:pubmed
pubmed-article:1675057pubmed:meshHeadingpubmed-meshheading:1675057-...lld:pubmed
pubmed-article:1675057pubmed:meshHeadingpubmed-meshheading:1675057-...lld:pubmed
pubmed-article:1675057pubmed:meshHeadingpubmed-meshheading:1675057-...lld:pubmed
pubmed-article:1675057pubmed:meshHeadingpubmed-meshheading:1675057-...lld:pubmed
pubmed-article:1675057pubmed:meshHeadingpubmed-meshheading:1675057-...lld:pubmed
pubmed-article:1675057pubmed:year1991lld:pubmed
pubmed-article:1675057pubmed:articleTitleExpression of c-erbB-2 in human pancreatic adenocarcinomas.lld:pubmed
pubmed-article:1675057pubmed:affiliationDepartment of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia.lld:pubmed
pubmed-article:1675057pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1675057pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:1675057pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1675057lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1675057lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1675057lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1675057lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1675057lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1675057lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1675057lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1675057lld:pubmed